摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1,2,5-三甲基-1H-吡咯-3-甲酰氯 | 147057-79-2

中文名称
1,2,5-三甲基-1H-吡咯-3-甲酰氯
中文别名
——
英文名称
1,2,5-Trimethyl-1H-pyrrole-3-carbonyl chloride
英文别名
1,2,5-trimethylpyrrole-3-carbonyl chloride
1,2,5-三甲基-1H-吡咯-3-甲酰氯化学式
CAS
147057-79-2
化学式
C8H10ClNO
mdl
MFCD04972634
分子量
171.62
InChiKey
SRZUCWIAAOZAOQ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    263.3±35.0 °C(Predicted)
  • 密度:
    1.16±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2
  • 重原子数:
    11
  • 可旋转键数:
    1
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.375
  • 拓扑面积:
    22
  • 氢给体数:
    0
  • 氢受体数:
    1

文献信息

  • [EN] INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES<br/>[FR] INGÉNOL-3-ACYLATES III ET INGÉNOL-3-CARBAMATES
    申请人:LEO PHARMA AS
    公开号:WO2012083953A1
    公开(公告)日:2012-06-28
    The invention relates to compounds of general formula I wherein R is heteroaryl optionally substituted by R7; or R is heterocycloalkyl or heterocycloalkenyl, optionally substituted by R8; or R is X wherein X is -NR11R12; and pharmaceutically acceptable salts, hydrates, or solvates thereof, for use -alone or in combination with one or more other pharmaceutically active compounds- in therapy, for preventing, treating or ameliorating diseases or conditions responsive to stimulation of neutrophil oxidative burst, responsive to stimulation of keratinocyte IL-8 release or responsive to induction of necrosis.
    该发明涉及一般式I的化合物,其中R为杂环芳基,可选择地由R7取代;或R为杂环烷基或杂环烯基,可选择地由R8取代;或R为X,其中X为-NR11R12;以及其在治疗中的药物可接受的盐、水合物或溶剂合物,用于单独使用或与一个或多个其他药用活性化合物结合在一起,用于预防、治疗或改善对中性粒细胞氧化爆发的刺激响应、对角质细胞IL-8释放的刺激响应或对坏死诱导的刺激响应的疾病或症状。
  • Imidazo[1,2-a] pyridine anxiolytics
    申请人:Fang Kevin
    公开号:US20050171144A1
    公开(公告)日:2005-08-04
    Imidazo[1,2-a]pyridines of the formulae I and II: are disclosed. The compounds are useful to treat anxiety and insomnia. Pharmaceutical compositions and methods are also disclosed. A representative compound of the invention is:
    公开了公式I和公式II的咪唑[1,2-a]吡啶化合物。这些化合物可用于治疗焦虑和失眠。还公开了制药组合物和方法。该发明的代表性化合物为:
  • Imidazo&lsqb;1,2-A&rsqb; Pyridine Anxiolytics
    申请人:Fang Q. Kevin
    公开号:US20080096867A1
    公开(公告)日:2008-04-24
    Imidazo[1,2-a]pyridines of the formulae I and II: are disclosed. The compounds are useful to treat anxiety and insomnia. Pharmaceutical compositions and methods are also disclosed. A representative compound of the invention is:
    公开了式I和式II的咪唑[1,2-a]吡啶化合物。这些化合物可用于治疗焦虑和失眠。还公开了制药组合物和方法。该发明的代表性化合物为:
  • IMIDAZO[1,2-A] PYRIDINE ANXIOLYTICS
    申请人:Fang Kevin
    公开号:US20070043074A1
    公开(公告)日:2007-02-22
    Imidazo[1,2- a ]pyridines of the formulae I and II: are disclosed. The compounds are useful to treat anxiety and insomnia. Pharmaceutical compositions and methods are also disclosed. A representative compound of the invention is:
    公开了式I和式II的咪唑[1,2-a]吡啶类化合物。该化合物可用于治疗焦虑和失眠。还公开了制药组合物和方法。该发明的代表化合物为:
  • INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES
    申请人:Grue-Sørensen Gunnar
    公开号:US20140303150A1
    公开(公告)日:2014-10-09
    The invention relates to compounds of general formula I wherein R is heteroaryl optionally substituted by R7; or R is heterocycloalkyl or heterocycloalkenyl, optionally substituted by R8; or R is X wherein X is —NR11R12; and pharmaceutically acceptable salts, hydrates, or solvates thereof, for use—alone or in combination with one or more other pharmaceutically active compounds—in therapy, for preventing, treating or ameliorating diseases or conditions responsive to stimulation of neutrophil oxidative burst, responsive to stimulation of keratinocyte IL-8 release or responsive to induction of necrosis.
    本发明涉及一般式I的化合物,其中R是杂环芳基,可选择由R7取代; 或R是杂环烷基或杂环烯基,可选择由R8取代; 或R是X,其中X是—NR11R12;以及其药学上可接受的盐、水合物或溶剂化物,用于治疗,单独或与一个或多个其他药学活性化合物联合使用,预防、治疗或改善对嗜中性粒细胞氧化爆发刺激、对角质细胞IL-8释放刺激或对坏死诱导反应的疾病或病情的响应。
查看更多